F
Filippo Russo
Researcher at Vita-Salute San Raffaele University
Publications - 57
Citations - 1515
Filippo Russo is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 14, co-authored 39 publications receiving 1174 citations.
Papers
More filters
Journal ArticleDOI
ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic Outcomes.
Giulio G. Stefanini,Matteo Montorfano,Daniela Trabattoni,Daniele Andreini,Giuseppe Ferrante,Marco Ancona,Marco Metra,Salvatore Curello,Diego Maffeo,Gaetano Pero,Michele Cacucci,Emilio Assanelli,Barbara Bellini,Filippo Russo,Alfonso Ielasi,Maurizio Tespili,Gian Battista Danzi,Pietro Vandoni,Mario Bollati,Lucia Barbieri,Jacopo Oreglia,Corrado Lettieri,Alberto Cremonesi,Stefano Carugo,Bernhard Reimers,Gianluigi Condorelli,Alaide Chieffo +26 more
TL;DR: In this paper, the authors propose a method to solve the problem of "missing links".http://www.theguardian.com/blogs/blogs-and-blogs.
Journal ArticleDOI
Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes
Marco Valgimigli,Enrico Frigoli,Sergio Leonardi,Martina Rothenbühler,Andrea Gagnor,Paolo Calabrò,Stefano Garducci,Paolo Rubartelli,Carlo Briguori,Giuseppe Andò,Alessandra Repetto,Ugo Limbruno,Roberto Garbo,Paolo Sganzerla,Filippo Russo,Alessandro Lupi,Bernardo Cortese,Arturo Ausiello,Salvatore Ierna,Giovanni Esposito,Patrizia Presbitero,Andrea Santarelli,Gennaro Sardella,Ferdinando Varbella,Simone Tresoldi,Nicoletta De Cesare,Stefano Rigattieri,Antonio Zingarelli,Paolo Tosi,Arnoud W J van 't Hof,Giacomo Boccuzzi,Elmir Omerovic,Manel Sabaté,Dik Heg,Peter Jüni,Pascal Vranckx +35 more
TL;DR: In patients with an acute coronary syndrome, the rates of major adverse cardiovascular events and net adverse clinical events were not significantly lower with bivalirudin than with unfractionated heparin.
Journal ArticleDOI
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Marco Valgimigli,Enrico Frigoli,Sergio Leonardi,Pascal Vranckx,Martina Rothenbühler,Matteo Tebaldi,Ferdinando Varbella,Paolo Calabrò,Stefano Garducci,Paolo Rubartelli,Carlo Briguori,Giuseppe Andò,Maurizio Ferrario,Ugo Limbruno,Roberto Garbo,Paolo Sganzerla,Filippo Russo,Marco Stefano Nazzaro,Alessandro Lupi,Bernardo Cortese,Arturo Ausiello,Salvatore Ierna,Giovanni Esposito,Giuseppe Ferrante,Andrea Santarelli,Gennaro Sardella,Nicoletta De Cesare,Paolo Tosi,Arnoud W J van 't Hof,Elmir Omerovic,Salvatore Brugaletta,Stephan Windecker,Dik Heg,Peter Jüni,Gianluca Campo,Lucia Uguccioni,Corrado Tamburino,Patrizia Presbitero,Dennis Zavalloni-Parenti,Fabio Ferrari,Roberto Ceravolo,Fabio Tarantino,Giampaolo Pasquetto,Gavino Casu,Stefano Mameli,Maria Letizia Stochino,Pietro Mazzarotto,Alberto Cremonesi,Francesco Saia,Giovanni Saccone,Fabio Abate,Andrea Picchi,Roberto Violini,Salvatore Colangelo,Giacomo Boccuzzi,Vincenzo Guiducci,Carlo Vigna,Antonio Zingarelli,Andrea Gagnor,Tiziana Zaro,Simone Tresoldi,Pietro Vandoni,Marco Contarini,Armando Liso,Dellavalle A,Salvatore Curello,Fabio Mangiacapra,Rosario Evola,Cataldo Palmieri,Camillo Falcone,Francesco Liistro,Manuela Creaco,Antonio Colombo,Alaide Chieffo,Andrea Perkan,Stefano De Servi,Dionigi Fischetti,Stefano Rigattieri,Alessandro Sciahbasi,Edoardo Pucci,Enrico Romagnoli,Claudio Moretti,Luciano Moretti,Raffaele De Caterina,Marcello Caputo,Marco Zimmarino,Ezio Bramucci,Emilio Di Lorenzo,Maurizio Turturo,Roberto Bonmassari,Carlo Penzo,Bruno Loi,Ciro Mauro,Anna Sonia Petronio,Gabriele Gabrielli,Antonio Micari,Flavia Belloni,Francesco Amico,Marco Comeglio,Claudio Fresco,Isala Klinieken,Nicolas M. Van Mieghem,Roberto Diletti,Evelyn Regar,Manel Sabaté,José Francisco Díaz Fernández,Vicente Mainar,José M. de la Torre Hernández +107 more
TL;DR: The prespecified final 1-year outcomes of the MATRIX programme, designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional glycoprotein IIb/IIIa inhibitors in patients with the whole spectrum of acute coronary syndrome undergoing invasive management, are described.
Journal ArticleDOI
Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX.
Giuseppe Andò,Bernardo Cortese,Filippo Russo,Martina Rothenbühler,Enrico Frigoli,Giuseppe Gargiulo,Carlo Briguori,Pascal Vranckx,Sergio Leonardi,Vincenzo Guiducci,Flavia Belloni,Fabio Ferrari,José M. de la Torre Hernández,Salvatore Curello,Francesco Liistro,Andrea Perkan,Stefano De Servi,Gavino Casu,Dellavalle A,Dionigi Fischetti,Antonio Micari,Bruno Loi,Fabio Mangiacapra,Nunzio Russo,Fabio Tarantino,Francesco Saia,Dik Heg,Stephan Windecker,Peter Jüni,Marco Valgimigli,Matrix Investigators +30 more
TL;DR: In ACS patients who underwent invasive management, RA was associated with a reduced risk of AKI compared with FA, and Stratified analyses suggested greater benefit with RA than FA in patients at greater risk for AKI.
Journal ArticleDOI
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.
Gianluca Campo,Luca Fileti,Nicoletta De Cesare,Emanuele Meliga,Alessandro Furgieri,Filippo Russo,Salvatore Colangelo,Salvatore Brugaletta,Roberto Ferrari,Marco Valgimigli,R Investigators +10 more
TL;DR: Poor response to clopidogrel is an independent predictor of periprocedural myocardial infarction and worse 1-year outcome in low-risk patients undergoing PCI, whereas poor response to aspirin failed to predict a worse outcome.